S2-E25.3 – Prevalence of NAFLD and NASH 2021 — An Urgent Call To Action

Louise Campbell and Roger Green join co-authors Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gawrieh to discuss why this epidemiology paper from the 2021 Journal of Hepatology is an urgent call to action for NAFLD and NASH screening and treatment.

Considered in its totality, the data coming from the 2021 Journal of Hepatology paper “Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort” come across as a clarion call to screen unaware, asymptomatic patients more aggressively and treat them more intently, even before we have new, approved medications in market. Whether you are familiar with the paper or not, you will want to hear why the panelists consider this data so compelling and their call to action so urgent.

TOPICS: AASLD, COVID-19, Diabetes, Diagnostic Tests, EchoSens, education, Fibrosis Level 3, MRI-PDFF, NAFLD, NASH, non-invasive liver testing, Obesity, Perspectum Diagnostics, population screening, social policy, Fibrosis Level 2, Epidemiology, San Antonia Military Medical Center,

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Request A Transcript of This Episode
Request Transcript
First
Last

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"